APA

Pellegrin I., Thiébaut R., Blanco P., Viallard J., Schrive M., Merel P., Chêne G., Fleury H., Moreau J. & Pellegrin J. (20051019). Can highly active antiretroviral therapy be interrupted in patients with sustained moderate HIV RNA and > 400 CD4+ cells/microl? Impact on immunovirological parameters. : Journal of medical virology.

Chicago

Pellegrin Isabelle, Thiébaut Rodolphe, Blanco Patrick, Viallard Jean-François, Schrive Marie-Hélène, Merel Patrick, Chêne Geneviève, Fleury Hervé, Moreau Jean-François and Pellegrin Jean-Luc. 20051019. Can highly active antiretroviral therapy be interrupted in patients with sustained moderate HIV RNA and > 400 CD4+ cells/microl? Impact on immunovirological parameters. : Journal of medical virology.

Harvard

Pellegrin I., Thiébaut R., Blanco P., Viallard J., Schrive M., Merel P., Chêne G., Fleury H., Moreau J. and Pellegrin J. (20051019). Can highly active antiretroviral therapy be interrupted in patients with sustained moderate HIV RNA and > 400 CD4+ cells/microl? Impact on immunovirological parameters. : Journal of medical virology.

MLA

Pellegrin Isabelle, Thiébaut Rodolphe, Blanco Patrick, Viallard Jean-François, Schrive Marie-Hélène, Merel Patrick, Chêne Geneviève, Fleury Hervé, Moreau Jean-François and Pellegrin Jean-Luc. Can highly active antiretroviral therapy be interrupted in patients with sustained moderate HIV RNA and > 400 CD4+ cells/microl? Impact on immunovirological parameters. : Journal of medical virology. 20051019.